 Tetrazoles
"Tetrazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
No definition found.
| Descriptor ID |
D013777
|
| MeSH Number(s) |
D03.383.129.617
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Tetrazoles".
Below are MeSH descriptors whose meaning is more specific than "Tetrazoles".
This graph shows the total number of publications written about "Tetrazoles" by people in this website by year, and whether "Tetrazoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1994 | 1 | 0 | 1 | | 1997 | 2 | 0 | 2 | | 1999 | 2 | 0 | 2 | | 2000 | 3 | 0 | 3 | | 2001 | 3 | 3 | 6 | | 2002 | 1 | 0 | 1 | | 2003 | 7 | 0 | 7 | | 2004 | 8 | 2 | 10 | | 2005 | 12 | 2 | 14 | | 2006 | 12 | 8 | 20 | | 2007 | 10 | 5 | 15 | | 2008 | 10 | 11 | 21 | | 2009 | 5 | 2 | 7 | | 2010 | 8 | 7 | 15 | | 2011 | 5 | 2 | 7 | | 2012 | 6 | 3 | 9 | | 2013 | 6 | 4 | 10 | | 2014 | 13 | 4 | 17 | | 2015 | 11 | 2 | 13 | | 2016 | 17 | 1 | 18 | | 2017 | 13 | 2 | 15 | | 2018 | 4 | 3 | 7 |
To return to the timeline, click here.
Below are the most recent publications written about "Tetrazoles" by people in Profiles.
-
Bouabdallaoui N, Claggett B, Zile MR, McMurray JJV, O'Meara E, Packer M, Prescott MF, Swedberg K, Solomon SD, Rouleau JL. Growth differentiation factor-15 is not modified by sacubitril/valsartan and is an independent marker of risk in patients with heart failure and reduced ejection fraction: the PARADIGM-HF trial. Eur J Heart Fail. 2018 12; 20(12):1701-1709.
-
O'Meara E, Prescott MF, Claggett B, Rouleau JL, Chiang LM, Solomon SD, Packer M, McMurray JJV, Zile MR. Independent Prognostic Value of Serum Soluble ST2 Measurements in Patients With Heart Failure and a Reduced Ejection Fraction in the PARADIGM-HF Trial (Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 05; 11(5):e004446.
-
Packer M, Claggett B, Lefkowitz MP, McMurray JJV, Rouleau JL, Solomon SD, Zile MR. Effect of neprilysin inhibition on renal function in patients with type 2 diabetes and chronic heart failure who are receiving target doses of inhibitors of the renin-angiotensin system: a secondary analysis of the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2018 07; 6(7):547-554.
-
Vardeny O, Claggett B, Kachadourian J, Pearson SM, Desai AS, Packer M, Rouleau J, Zile MR, Swedberg K, Lefkowitz M, Shi V, McMurray JJV, Solomon SD. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). Circ Heart Fail. 2018 04; 11(4):e004745.
-
Rolston KVI, Reitzel R, Vargas-Cruz N, Shelburne SA, Raad II, Prince RA. In vitro activity of tedizolid and comparator agents against clinical Gram-positive isolates recovered from patients with cancer. Diagn Microbiol Infect Dis. 2018 Aug; 91(4):351-353.
-
Mogensen UM, Gong J, Jhund PS, Shen L, Køber L, Desai AS, Lefkowitz MP, Packer M, Rouleau JL, Solomon SD, Claggett BL, Swedberg K, Zile MR, Mueller-Velten G, McMurray JJV. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2018 04; 20(4):760-768.
-
Lund LH, Claggett B, Liu J, Lam CS, Jhund PS, Rosano GM, Swedberg K, Yusuf S, Granger CB, Pfeffer MA, McMurray JJV, Solomon SD. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. Eur J Heart Fail. 2018 08; 20(8):1230-1239.
-
McMurray JJV, Trueman D, Hancock E, Cowie MR, Briggs A, Taylor M, Mumby-Croft J, Woodcock F, Lacey M, Haroun R, Deschaseaux C. Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart. 2018 06; 104(12):1006-1013.
-
Wolsk E, Claggett B, Køber L, Pocock S, Yusuf S, Swedberg K, McMurray JJV, Granger CB, Pfeffer MA, Solomon SD. Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. Eur J Heart Fail. 2018 03; 20(3):504-510.
-
Mogensen UM, Køber L, Jhund PS, Desai AS, Senni M, Kristensen SL, Dukát A, Chen CH, Ramires F, Lefkowitz MP, Prescott MF, Shi VC, Rouleau JL, Solomon SD, Swedberg K, Packer M, McMurray JJV. Sacubitril/valsartan reduces serum uric acid concentration, an independent predictor of adverse outcomes in PARADIGM-HF. Eur J Heart Fail. 2018 03; 20(3):514-522.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|